Pulmonary Vascular Disease News

Among patients with HF, empagliflozin lowered diastolic pulmonary artery pressure and was effective at reducing CV death and HF hospitalizations regardless of sacubitril/valsartan use, researchers reported.

In patients with HF with preserved ejection fraction and pulmonary hypertension, levosimendan did not meet its primary endpoint but met two secondary endpoints, according to results from the phase 2 HELP-PH-HFpEF trial.

The Healio editors have compiled a list of the most-read pulmonology news published in September.

Patients with pulmonary arterial hypertension at intermediate risk who switched from phosphodiesterase type 5 inhibitors to riociguat experienced clinical improvement at 24 weeks, according to results of the REPLACE study.

Combination therapy with pirfenidone plus sildenafil did not provide treatment benefit in patients with advanced idiopathic pulmonary fibrosis and risk for pulmonary hypertension compared with pirfenidone plus placebo.

New data from the HOME-PE trial support outpatient management of patients with acute pulmonary embolism using two different triaging strategies.

The Healio editors have compiled a list of the most-read pulmonology news published in August.

Pulmonary vascular dilation appears to play a role in hypoxemia in patients with COVID-19-related pneumonia, researchers reported in a new study published in the American Journal of Respiratory and Critical Care Medicine.

The Healio editors have compiled a list of recent updates in the management and treatment of pulmonary hypertension.

In patients with newly diagnosed pulmonary arterial hypertension, initial triple oral therapy, compared with double therapy, both improved hemodynamics, NT-proBNP and functional capacity, with no difference between strategies at 26 weeks.